Health Canada has approved Alecensaro (alectinib) to treat patients with a rare form of lung cancer. The drug is approved as a first-line monotherapy for patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).
This most recent approval is for Imfinzi (durvalumab) to treat locally advanced, unresectable non-small cell lung cancer (NSCLC) following platinum-based chemoradiation therapy. The approval of Imfinzi was fast-tracked under Health Canada’s accelerated approval framework.
Health Canada has approved the expansion of the ovarian cancer drug Lynparza(olaparib) as maintenance therapy for adults with platinum-sensitive relapsed (PSR), high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial response) to platinum-based chemotherapy.
Health Canada has approved Novartis’ Kisqali (ribociclib) in combination with an aromatase inhibitor for the initial treatment for advanced or metastatic breast cancer in which postmenopausal women are hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative.